
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is in the later stage of clinical development, and analysts are optimistic about its potential to transform cancer treatment using its novel physics-based approach. With a promising lead product and partnerships with reputable companies such as JNJ, Nanobiotix has the potential for significant revenue streams through milestones and royalties. Risks include clinical and regulatory setbacks, commercial challenges, and potential funding needs before achieving positive cash flow. However, the recent royalty monetization agreement with HCRx and positive updates on trials have increased analyst confidence, leading to a PT revision to $36 per ADR from $26 previously.
Bears say
Nanobiotix is highly dependent on the success and approval of their lead product, NBTXR3, with a 50% probability of success in the LA HNSCC market and a 45% probability of success in the R/M HNSCC market, which poses significant risks to the company's growth and financial stability. In addition, their revenue projections heavily rely on milestone payments and royalty revenue, which could be impacted by any delays or failures in clinical trials. The company also faces risks such as potential legal issues and government intervention in drug pricing, which could impact their financial results.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares